Bio Pharma Dive

AUGUST 28, 2023

GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.

Drugs 246

Drugs Protein Medicine 246

Bio Pharma Dive

MAY 7, 2024

The company is using what it claims is the largest database of viral protein structures to unearth medicines for a range of diseases, said CEO and Flagship origination partner Lovisa Afzelius.

Protein 156

Protein Medicine Drugs 156

Pharma Times

DECEMBER 20, 2023

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.

Protein 99

Protein Medicine Engineer Genetics 99

Bio Pharma Dive

OCTOBER 24, 2023

The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.

Protein 300

Protein Medicine Drugs 300

Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 183

Protein Antibody Medicine Drugs 183

Bio Pharma Dive

OCTOBER 26, 2022

It joins a group of medicines on market that target a protein called BCMA. The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease.

Protein 284

Protein Antibody Medicine Drugs 284

Drug Discovery World

APRIL 17, 2024

Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR. We are thrilled to partner with an organisation that shares our dedication to delivering transformative medicines to patients with significant unmet need,” said John Houston, Chairperson, President and Chief Executive Officer of Arvinas. “We

Protein 52

Protein Licensing Licensing Sales 52

Medical Xpress

NOVEMBER 8, 2022

Researchers at the University of Maryland School of Medicine's (UMSOM) Center for Precision Disease Modeling identified how a specific protein in SARS-CoV-2, the virus responsible for COVID-19, damages heart tissue. They then used a drug to reverse the toxic effects of that protein on the heart.

Protein 98

Protein Medicine Drugs Research 98

Bio Pharma Dive

OCTOBER 20, 2022

The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

Protein 321

Protein Antibody Medicine Drugs 321

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Discover the top API protein and peptide companies in contract marketing. Technologies in the delivery of peptides and proteins. They are promising therapeutics for the treatment of a variety of metabolic and oncological disorders.

Protein 130

Protein Marketing Manufacturing Reagent 130

Drug Discovery World

FEBRUARY 12, 2024

million grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. Membrane proteins are crucial molecules on the surface of cells with numerous biological functions, such as sensing hormones or cell communication.

Research 105

Research Drugs Engineer Protein 105

Bio Pharma Dive

MAY 18, 2021

The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.

Protein 333

Protein Antibody Medicine Drugs 333

Drug Discovery World

MAY 4, 2023

Adaptyv Bio, a Swiss/US technology company that develops infrastructure and tools for protein designers to engineer better proteins, has built a protein engineering foundry that it says will “pave the way” for protein designers to develop new medicines, novel enzymes and sustainable materials.

Engineer 52

Engineer Protein Life Science Medicine 52

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Drug Discovery World

FEBRUARY 13, 2024

It goes on to show that NX-2127, a potent targeted protein degrader with differentiated activity against BTK and IKZF1/3, can overcome this resistance across a broad range of acquired mutations. The post Protein degrader overcomes resistance in B-cell malignancies appeared first on Drug Discovery World (DDW).

Protein 52

Protein Medicine Scientist Research 52

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Scienmag

JUNE 10, 2022

PHILADELPHIA — A stress protein that is overactive in many types of tumor cells also has a key role in tumor-supporting cells called fibroblasts, and may be a good target for future cancer treatments, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

Protein 83

Protein Medicine Drugs Research 83

Drug Discovery World

FEBRUARY 7, 2024

Professor Jonathan Blackburn, Chief Scientific Officer (CSO) of Sengenics, featured in a sponsored DDW Sitting Down With podcast to discuss the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more. Sengenics can also help comb through all the data.

Medicine 59

Medicine Protein FDA Approval DNA 59

Pharmaceutical Technology

JULY 7, 2022

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Often referred to as a type of gene-modified cell therapy, CAR-T cell therapies involve genetically modifying a patient’s own T cells to produce a protein that enables them to identify and kill cancer cells.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. With a silenced effector function, ALE.F02 has been designed for targeting the stiff ECM of fibrotic tissues and organs.

Medicine 130

Medicine Development Antibody Engineer 130

Scienmag

FEBRUARY 18, 2022

CAMBRIDGE, MA — MIT chemists have discovered the structure of a protein that can pump toxic molecules out of bacterial cells. Proteins similar to this one, which is found in E. coli, are believed to help bacteria become resistant to multiple antibiotics.

Protein 82

Protein Bacteria Drugs Medicine 82

Drug Discovery World

JULY 24, 2023

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

Scienmag

MARCH 26, 2021

Discovery opens door to testing more effective drugs for treating COVID-19 patients University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2–the virus that causes COVID-19 – and then used an FDA-approved cancer drug to blunt the viral protein’s detrimental effects.

Protein 71

Protein FDA Approval Drugs Medicine 71

Drug Discovery World

JANUARY 25, 2024

US company Vaxxinity and the University of Central Florida (UCF) have announced plans to work together to advance space medicine research. The post Immunotherapy partnership advances space medicine research appeared first on Drug Discovery World (DDW).

Medicine 52

Medicine Research In-Vivo In-Vitro 52

XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

BioTech 365

APRIL 21, 2021

Global Biochips Markets & Technologies Report 2021-2028: Microfluidics-based, Protein, Nanotechnology, Epigenetics, Drug Discovery & Development, Molecular Diagnostics & Personalized Medicine – ResearchAndMarkets.com Global Biochips Markets & Technologies Report 2021-2028: Microfluidics-based, Protein, Nanotechnology, Epigenetics, (..)

Protein 40

Protein Medicine Marketing Development 40

Drug Discovery World

MAY 18, 2023

Scientists in Japan have used a novel technique to identify a protein complex degraded by autophagy that has a possible role in liver cancer. p62 protein forms a membrane-less cytosolic organelle called p62 body and helps in the selective removal of toxic cellular waste through autophagy.

Protein 52

Protein Scientist Medicine Regulation 52

Drug Discovery World

SEPTEMBER 4, 2023

In the third and final part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates therapeutic breakthroughs using plant-based products in drug discovery. In this study, researchers discovered how EGCG breaks apart tangles of the protein tau, a ‘hallmark’ of Alzheimer’s disease.

Medicine 59

Medicine Protein Containment Drugs 59

Drug Discovery World

OCTOBER 5, 2023

The webinar ‘Generative AI: Turning drug discovery into a technological pursuit’ supported by Thermo Fisher Scientific and presented by Generate:Biomedicines will be free to attend on 12 October 9am EDT / 2pm BST / 3pm CEST.

Drugs 52

Drugs Protein Medicine 52

Drug Discovery World

APRIL 25, 2024

Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological understanding to inform future discovery. It employs a group of researchers who developed the leading models for protein and antibody design, RFdiffusion and RFantibody, while in Dr Baker’s lab.

Drugs 52

Drugs Protein Antibody Engineer 52

Drug Discovery World

JANUARY 20, 2023

Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells.

Medicine 52

Medicine Genotype Protein RNA 52

Drug Discovery World

SEPTEMBER 25, 2023

We are thrilled to partner with IDT and bring together their expertise in CRISPR chemistry and oligo production with Aldevron expertise in cGMP CRISPR nuclease and ribonucleoprotein (RNP) manufacturing,” added Tom Foti, Vice President and General Manager of Aldevron’s Protein Business Unit. “We

Genome 52

Genome Genomics Gene Editing Medicine 52

Drug Discovery World

FEBRUARY 16, 2023

Challenges remain with current delivery approaches, and genetic medicines applications have been generally restricted to the liver and ex vivo settings. The post Start-up aims to advance transformative genetic medicines appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Medicine Gene Editing In-Vivo 52

Pharmaceutical Technology

JANUARY 25, 2023

French biopharmaceutical firm Poxel has received orphan drug designation (ODD) from the European Commission (EC) for its molecules PXL770 and PXL065 to treat adrenoleukodystrophy (ALD). The latest move follows a positive opinion issued by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).

Drugs 130

Drugs Genome Genomics Medicine 130

Pharmaceutical Technology

JUNE 29, 2022

The pharmaceutical industry often relies on enzymes to perform a process known as biocatalysis, which facilitates the cost-effective and sustainable production of small molecule drugs at scale. The next wave of medicine is well on course to be cell and gene-based. Advantageous synergies within the Novo family make this a possibility.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

Drug Discovery World

SEPTEMBER 18, 2023

What you will learn: How AI and ML are transforming drug discovery How generative AI can produce novel proteins How this approach can bring tailored medicines to patients Register here to attend The post Webinar: Generative AI: Turning drug discovery into a technological pursuit appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Protein Medicine 52

Drug Discovery World

SEPTEMBER 26, 2023

What you will learn: How AI and ML are transforming drug discovery How generative AI can produce novel proteins How this approach can bring tailored medicines to patients Register here to attend. The post Webinar: How AI is transforming drug discovery appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Protein Medicine 52